Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
2601 2554.5 2510.5 2440 2531 Last
5093100 4440200 7087000 4538200 5872100 Volume
-0.73% -1.79% -1.72% -2.81% +3.73% Change
Estimated financial data (e)
Sales 2021 968 B 8 732 M 8 732 M
Net income 2021 58 345 M 526 M 526 M
Net cash position 2021 663 B 5 976 M 5 976 M
P/E ratio 2021 83,9x
Yield 2021 1,07%
Sales 2022 999 B 9 012 M 9 012 M
Net income 2022 57 761 M 521 M 521 M
Net cash position 2022 644 B 5 812 M 5 812 M
P/E ratio 2022 85,2x
Yield 2022 1,05%
Capitalization 4 850 B 43 776 M 43 736 M
EV / Sales 2021 4,32x
EV / Sales 2022 4,21x
Nbr of Employees 15 348
Free-Float 80,6%
More Financials
Company
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development,... 
Sector
Pharmaceuticals
Calendar
06/21Shareholder meeting
More about the company
Ratings of Daiichi Sankyo Company, Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about DAIICHI SANKYO COMPANY, LIMITED
02:30aDaiichi Sankyo to Issue Common Stocks to Employees Under Share Compensation P..
MT
06/22DAIICHI SANKYOá : Corporate Governance Report
PU
06/15Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment
RE
06/14Japanese shares inch higher, Toshiba up after ouster of board directors
RE
06/13Japanese shares track Wall Street higher, gains capped as investors await Fed..
RE
06/08Nikkei 225 Slips 0.2% on Inflation Outlook, Asian Market Softness
MT
06/08Heavyweights pull Nikkei lower, Topix gains on drugmakers' boost
RE
06/07Nikkei falls as market heavyweights offset gains in drugmakers
RE
06/02Japan shares rally as reopening hopes boosts travel, real estate firms
RE
06/01Japan shares rally as reopening hopes boosts travel, real estate firms
RE
05/31ETRIONá : Sells Niigata Solar Project for $57 Million, Expects Further Disposals..
MT
05/30Japanese shares retreat from 3-week high; drugmakers limit losses
RE
05/27Japan to consider sharing COVID-19 vaccines amid calls to help Taiwan
RE
05/21Japan approves more COVID-19 vaccines, expands state of emergency
RE
05/20Japan approves more COVID-19 vaccines, expands state of emergency
RE
More news
News in other languages on DAIICHI SANKYO COMPANY, LIMITED
06/14TOKYO STOCK EXCHANGE : Borsa Tokyo in rialzo, Toshiba avanza dopo estromissione ..
05/27Coronavirus-Le Japon envisage de fournir le vaccin d'AstraZeneca à Taiwan
05/27Coronavirus-Le Japon envisage de fournir le vaccin d'AstraZeneca à Taiwan-pre..
05/23Coronavirus-Le Japon ouvre deux vaccinodromes en amont des Jeux olympiques
05/21Tokyo finit en hausse, portée par Wall Street et des vaccins
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 531,00 JPY
Average target price 3 665,38 JPY
Spread / Average Target 44,8%
EPS Revisions
Managers and Directors
NameTitle
Sunao Manabe President, CEO & Representative Director
Toshiaki Sai CFO, Representative Director & Executive VP
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED-28.40%43 776
JOHNSON & JOHNSON3.96%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.7.61%221 725
NOVARTIS AG2.56%209 282
ABBVIE INC.7.05%202 586